Datopotamab deruxtecan by Daiichi Sankyo for Peritoneal Cancer: Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Peritoneal Cancer.
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Peritoneal Cancer.
What's Your Reaction?
